These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11480457)

  • 1. Troglitazone improves endothelial dysfunction in patients with insulin resistance.
    Watanabe Y; Sunayama S; Shimada K; Sawano M; Hoshi S; Iwama Y; Mokuno H; Daida H; Yamaguchi H
    J Atheroscler Thromb; 2000; 7(3):159-63. PubMed ID: 11480457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
    Tack CJ; Ong MK; Lutterman JA; Smits P
    Diabetologia; 1998 May; 41(5):569-76. PubMed ID: 9628275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.
    Avena R; Mitchell ME; Nylen ES; Curry KM; Sidawy AN
    J Vasc Surg; 1998 Dec; 28(6):1024-31; discussion 1031-2. PubMed ID: 9845653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance.
    Miles PD; Higo K; Romeo OM; Lee MK; Rafaat K; Olefsky JM
    Diabetes; 1998 Mar; 47(3):395-400. PubMed ID: 9519745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
    Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
    Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
    Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
    Miles PD; Romeo OM; Higo K; Cohen A; Rafaat K; Olefsky JM
    Diabetes; 1997 Nov; 46(11):1678-83. PubMed ID: 9356012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
    Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
    J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP; Yu JG; Kruszynska YT; Olefsky JM
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus.
    Sekiya M; Suzuki J; Watanabe K; Funada J; Otani T; Akutsu H
    Jpn Circ J; 2001 Jun; 65(6):487-90. PubMed ID: 11407727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
    Willi SM; Kennedy A; Wallace P; Ganaway E; Rogers NL; Garvey WT
    Diabetes; 2002 Oct; 51(10):2895-902. PubMed ID: 12351424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
    Yagi N; Takasu N; Higa S; Ishikawa K; Murakami K; Mimura G
    Horm Metab Res; 1995 Oct; 27(10):439-41. PubMed ID: 8575720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
    Lee MK; Miles PD; Khoursheed M; Gao KM; Moossa AR; Olefsky JM
    Diabetes; 1994 Dec; 43(12):1435-9. PubMed ID: 7958495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis.
    Zhang B; Saku K; Arakawa K
    Metabolism; 1997 Mar; 46(3):273-81. PubMed ID: 9054469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
    Buras J; Reenstra WR; Orlow D; Horton ES; Veves A
    Obes Res; 2005 Jul; 13(7):1167-74. PubMed ID: 16076985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells.
    de Dios ST; Hannan KM; Dilley RJ; Hill MA; Little PJ
    J Diabetes Complications; 2001; 15(3):120-7. PubMed ID: 11358680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
    Khoursheed M; Miles PD; Gao KM; Lee MK; Moossa AR; Olefsky JM
    Metabolism; 1995 Nov; 44(11):1489-94. PubMed ID: 7476339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
    Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
    N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.
    Schneider F; Vossler S; Franke S; Bär F; Konrad T
    Int J Clin Pharmacol Ther; 2009 May; 47(5):311-20. PubMed ID: 19473593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.